<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Establishment Labs Holdings Inc. Jefferies London Healthcare Conference 2025 Transcript</td><td># ì—ìŠ¤íƒ€ë¸”ë¦¬ì‹œë¨¼íŠ¸ ë©ìŠ¤ í™€ë”©ìŠ¤ Jefferies ëŸ°ë˜ í—¬ìŠ¤ì¼€ì–´ ì»¨í¼ëŸ°ìŠ¤ 2025 ë…¹ì·¨ë¡<br><br>**ë°œí‘œì:**<br>- íšŒì‚¬ ê²½ì˜ì§„<br><br>**ì£¼ìš” ë‚´ìš©:**<br><br>[ì°¸ê³ : ì‹¤ì œ ë…¹ì·¨ë¡ ë‚´ìš©ì´ ì œê³µë˜ì§€ ì•Šì•„ ì¼ë°˜ì ì¸ í˜•ì‹ë§Œ í‘œì‹œí•©ë‹ˆë‹¤]<br><br>**ê²½ì˜ì§„ ë°œí‘œ:**<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. Jefferies ëŸ°ë˜ í—¬ìŠ¤ì¼€ì–´ ì»¨í¼ëŸ°ìŠ¤ì— ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>**ì¬ë¬´ ì‹¤ì  ë° ì „ë§:**<br><br>[ë…¹ì·¨ë¡ ë³¸ë¬¸ì´ ì œê³µë˜ë©´ ì—¬ê¸°ì— ë²ˆì—­ì´ ë“¤ì–´ê°‘ë‹ˆë‹¤]<br><br>**ì§ˆì˜ì‘ë‹µ:**<br><br>[Q&A ì„¸ì…˜ ë‚´ìš©]<br><br>---<br><br>*ë³¸ ë²ˆì—­ë³¸ì€ íˆ¬ìì ì •ë³´ ì œê³µ ëª©ì ìœ¼ë¡œ ì‘ì„±ë˜ì—ˆìŠµë‹ˆë‹¤. íˆ¬ì ê²°ì • ì‹œ ì›ë¬¸ì„ ë°˜ë“œì‹œ ì°¸ê³ í•˜ì‹œê¸° ë°”ëë‹ˆë‹¤.*<br><br>---<br><br>ì œê³µí•˜ì‹  ì´ë¯¸ì§€ë‚˜ ë¬¸ì„œì— ì‹¤ì œ ì»¨í¼ëŸ°ìŠ¤ ë…¹ì·¨ë¡ ë‚´ìš©ì´ í¬í•¨ë˜ì–´ ìˆë‹¤ë©´, í•´ë‹¹ ë‚´ìš©ì„ ê³µìœ í•´ ì£¼ì‹œë©´ ì •í™•í•œ ì „ë¬¸ ë²ˆì—­ì„ ì œê³µí•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. <br><br>ì¬ë¬´ ìš©ì–´ì˜ ì •í™•í•œ ë²ˆì—­ì„ ìœ„í•´ ë‹¤ìŒê³¼ ê°™ì€ ìš©ì–´ë“¤ì„ ì¼ê´€ë˜ê²Œ ì‚¬ìš©í•©ë‹ˆë‹¤:<br>- Revenue: ë§¤ì¶œ<br>- EBITDA: ì„¸ì „ì˜ì—…ì´ìµ<br>- Gross Margin: ë§¤ì¶œì´ì´ìµë¥ <br>- Operating Expenses: ì˜ì—…ë¹„ìš©<br>- Cash Flow: í˜„ê¸ˆíë¦„<br><br>ì¶”ê°€ ë‚´ìš©ì„ ì œê³µí•´ ì£¼ì‹œë©´ ìƒì„¸í•œ ë²ˆì—­ì„ ì§„í–‰í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Establishment Labs Holdings Inc. - Jefferies London Healthcare Conference 2025 ìš”ì•½<br><br>**ì£¼ìš” ì¬ë¬´ ì§€í‘œ ë° ì‹¤ì :**<br>- êµ¬ì²´ì ì¸ ì¬ë¬´ ìˆ˜ì¹˜ë‚˜ ìµœê·¼ ë¶„ê¸° ì‹¤ì ì— ëŒ€í•œ ì–¸ê¸‰ì´ ì œê³µëœ ì „ì‚¬ë¡ì— í¬í•¨ë˜ì–´ ìˆì§€ ì•ŠìŒ<br>- ì»¨í¼ëŸ°ìŠ¤ í”„ë ˆì  í…Œì´ì…˜ í˜•ì‹ìœ¼ë¡œ ì„¸ë¶€ ìˆ˜ì¹˜ í™•ì¸ ë¶ˆê°€<br><br>**ê²½ì˜ì§„ í†¤ ë° ì „ëµì  ë°©í–¥:**<br>- ì „ì‚¬ë¡ ë‚´ìš©ì´ ì œê³µë˜ì§€ ì•Šì•„ ê²½ì˜ì§„ì˜ ë°œì–¸ í†¤, ì‚¬ì—… ì „ëµ, ì‹œì¥ ê¸°íšŒì— ëŒ€í•œ ê²¬í•´ë¥¼ íŒŒì•…í•  ìˆ˜ ì—†ìŒ<br><br>**ê°€ì´ë˜ìŠ¤ ë° ì „ë§:**<br>- 2025ë…„ ë˜ëŠ” í–¥í›„ ê¸°ê°„ì— ëŒ€í•œ ë§¤ì¶œ ê°€ì´ë˜ìŠ¤, ìˆ˜ìµì„± ëª©í‘œ ë“±ì´ ì „ì‚¬ë¡ì—ì„œ í™•ì¸ë˜ì§€ ì•ŠìŒ<br><br>**ë¦¬ìŠ¤í¬ ë° ê°•ì :**<br>- ì œê³µëœ ì •ë³´ ë¶€ì¡±ìœ¼ë¡œ íšŒì‚¬ê°€ ì§ë©´í•œ ê·œì œ ë¦¬ìŠ¤í¬, ê²½ìŸ í™˜ê²½, ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ ê°•ì  ë“±ì„ ë¶„ì„í•  ìˆ˜ ì—†ìŒ<br><br>**ì°¸ê³ ì‚¬í•­:**<br>- ì™„ì „í•œ ë¶„ì„ì„ ìœ„í•´ì„œëŠ” ì‹¤ì œ ì»¨í¼ëŸ°ìŠ¤ ì „ì‚¬ë¡ ì „ë¬¸ì´ í•„ìš”í•¨</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Doesn't make sense.: Peter Caldini: If you do look at, and having worked in a lot of these big multinationals, that's a common, you know, that's a common process. At a certain point, they're going to get to the level where it doesn't make sense to maintain the business. When that happens, I don't know, but, you know, I think that could be a reality. Matt Taylor: I guess going back to international, you know, I think with the success you've had so far in the U.S., you've convinced a lot of investors that you're going to be a big player there. What about your ability to continue to drive growth in international, broadly speaking, where there has also been sort of a tough macro environment for a few years? Peter Caldini: Yeah, I think overall, I think the macro environment has been stable, as I mentioned. I think there are certain areas where you have good growth from a market standpoint, but there are some challenges. We highlighted China. You know, for us, we're very pleased with the progress we made this year in our OUS markets. We made a strategic decision to really focus on the direct markets. You know, these are markets, these are the larger markets. You know, when you talk about Western Europe, we have much better revenue potential. You know, we've dedicated a lot of resources, and we reallocate a lot of our resources from distributor markets to direct markets to really take advantage of the opportunities. In these markets, we have much better economics. You know, we've seen a lot of success. You know, I mentioned before the growth rates in Western Europe, 20% growth. Peter Caldini: You know, we're stealing share in a lot of these markets. We've been adding a number of accounts in Western Europe. We've added about 10% across all our direct markets. Preserve and the minimally invasive platform is really helping drive a lot of that growth. You know, for me, that's going to be, you know, a key growth driver for us. It's going to help drive the profitability as well. You know, I think we've made a lot of good traction so far, and that's going to continue in Q4 all the way through 2026 and beyond. Matt Taylor: Maybe we'll end on a few questions on the pipeline. You've always described yourselves as a women's health company. I think a lot of investors don't even know about JEM. Maybe we could start by talking about the JEM program, you know, where that is and what kind of an opportunity that could be in the future. Peter Caldini: Yeah, you know, I think we don't talk about it a lot because we have so much close in. You know, when I think you look at the breast augmentation, the Recon Indication in the U.S., I think for JEM, that's a later down pipeline opportunity. I think it could be a very sizable opportunity. We're going to be first looking at launching that in Latin America, probably around late 2026, 2027. A lot of this is going to be dependent on the regulatory pathways in the U.S. and also in Europe. I think in Latin America, it's going to be a little bit easier. I think that's going to be really after really leveraging and utilizing the opportunities we have in terms of the breast augmentation space. That's going to be something that's going to really fuel the growth in 2028 and beyond. Matt Taylor: Could you describe what JEM is, the value proposition and the unmet need it addresses? Raj Denhoy: Yeah, so it's in the gluteal augmentation space, right, which is a market that is sizable and has grown over the last few years. The, you know, currently available technologies there are pretty substandard. There's not been much innovation at all. Frankly, some of the injections and fillers that are used can be quite dangerous. We are taking some of the core technologies we have in our minimally invasive portfolio, the injection device, the implants, and really adapting them to use in a gluteal augmentation approach. As Peter noted, it's still in clinicals, and we're still working through this. For what we've seen, it's very encouraging. It is really a pipeline product to really think about it contributing, as Peter noted, in 2027 and beyond. The opportunity is there. Raj Denhoy: We believe we have something that's pretty unique and differentiated, and you'll hear more from us over the next couple of years on it. Matt Taylor: Maybe I'll end on a fun one. You're very popular on Instagram. Raj Denhoy: Meet Raj? Peter Caldini: Yeah. Matt Taylor: The company. You have also had, you know, some signups of brand ambassadors and are doing some marketing that way. Maybe just talk a little bit about that strategy to get recognition of the brand and kind of the buzz that is being created by some of the online marketing. Peter Caldini: Yeah, I think, you know, especially you see this in the U.S. I mean, we did the Meghan Trainor campaign. That's been tremendously successful for us, not only to create the interest. We've been able to track the number of patients that have come in specifically on that program. Also, I think we've just overall been able to create a lot of buzz in the industry. Some of that is driven by us, and a lot of it's driven also by the surgeons. You know, I think in some respects, there really hasn't been, you know, a lot of innovation coming to the market in the U.S. I think once we came in and we provided a lot of materials, I think, you know, along with the things that we're doing, the surgeons are also very excited about it. Peter Caldini: You see them doing a lot of posting and reposting. I think that's really been able to drive a lot of the growth. I think for us, it's very unusual that you have patients walking in, talking to surgeons, and asking specifically for Motiva. You know, we're very proud about the efforts. That really helps us to drive the penetration and the utilization rates. That's going to continue into 2026 and beyond. Matt Taylor: Great. I'll be waiting for my contract. Peter Caldini: I'm not sure you're the right target, though. Matt Taylor: All right. Thank you guys for your time, and thanks everybody for your interest in this action. Peter Caldini: Thank you. Raj Denhoy: Thank you.</td><td>**Doesn't make sense.:** ë§ì€ ëŒ€í˜• ë‹¤êµ­ì  ê¸°ì—…ë“¤ì—ì„œ ì¼í•´ë³¸ ê²½í—˜ìœ¼ë¡œ ë³¼ ë•Œ, ì´ëŸ° ê³¼ì •ì€ í”í•œ ì¼ì…ë‹ˆë‹¤. ì–´ëŠ ì‹œì ì´ ë˜ë©´ ì‚¬ì—…ì„ ìœ ì§€í•˜ëŠ” ê²ƒì´ ë” ì´ìƒ ì˜ë¯¸ê°€ ì—†ëŠ” ìˆ˜ì¤€ì— ë„ë‹¬í•˜ê²Œ ë©ë‹ˆë‹¤. ê·¸ê²Œ ì–¸ì œê°€ ë ì§€ëŠ” ëª¨ë¥´ê² ì§€ë§Œ, ì¶©ë¶„íˆ í˜„ì‹¤ì´ ë  ìˆ˜ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>êµ­ì œ ì‚¬ì—…ìœ¼ë¡œ ë‹¤ì‹œ ëŒì•„ê°€ì„œ ë§ì”€ë“œë¦¬ìë©´, ë¯¸êµ­ì—ì„œ ì§€ê¸ˆê¹Œì§€ ê±°ë‘” ì„±ê³µìœ¼ë¡œ ë§ì€ íˆ¬ììë“¤ê»˜ ìš°ë¦¬ê°€ ê·¸ ì‹œì¥ì—ì„œ ì£¼ìš” í”Œë ˆì´ì–´ê°€ ë  ê²ƒì´ë¼ëŠ” í™•ì‹ ì„ ë“œë¦° ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ êµ­ì œ ì‹œì¥ì—ì„œì˜ ì§€ì†ì ì¸ ì„±ì¥ ê²¬ì¸ ëŠ¥ë ¥ì€ ì–´ë–»ìŠµë‹ˆê¹Œ? êµ­ì œ ì‹œì¥ë„ ëª‡ ë…„ê°„ ì–´ë ¤ìš´ ê±°ì‹œê²½ì œ í™˜ê²½ì„ ê²ªì–´ì™”ëŠ”ë°ìš”.<br><br>ì „ë°˜ì ìœ¼ë¡œ ë³¼ ë•Œ, ì œê°€ ë§ì”€ë“œë ¸ë“¯ì´ ê±°ì‹œê²½ì œ í™˜ê²½ì€ ì•ˆì •ì ì´ì—ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì‹œì¥ ê´€ì ì—ì„œ ë³´ë©´ ì„±ì¥ì„¸ê°€ ì¢‹ì€ ë¶„ì•¼ë“¤ì´ ìˆì§€ë§Œ, ë™ì‹œì— ëª‡ ê°€ì§€ ê³¼ì œë„ ì¡´ì¬í•©ë‹ˆë‹¤. ì¤‘êµ­ ì‹œì¥ì„ ì˜ˆë¡œ ë“¤ ìˆ˜ ìˆê² ìŠµë‹ˆë‹¤. ì €í¬ë¡œì„œëŠ” ì˜¬í•´ í•´ì™¸ì‹œì¥(OUS)ì—ì„œ ì´ë£¬ ì„±ê³¼ì— ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì§ì ‘ ì‹œì¥ì— ì§‘ì¤‘í•˜ê¸°ë¡œ ì „ëµì  ê²°ì •ì„ ë‚´ë ¸ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì‹œì¥ë“¤ì€ ê·œëª¨ê°€ í° ì‹œì¥ë“¤ì´ì£ . ì„œìœ ëŸ½ì„ ì˜ˆë¡œ ë“¤ë©´, í›¨ì”¬ ë” ë‚˜ì€ ë§¤ì¶œ ì ì¬ë ¥ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ë§ì€ ìì›ì„ íˆ¬ì…í–ˆê³ , ìœ í†µì—…ì²´ ì‹œì¥ì—ì„œ ì§ì ‘ ì‹œì¥ìœ¼ë¡œ ìì›ì„ ëŒ€ê±° ì¬ë°°ì¹˜í•˜ì—¬ ê¸°íšŒë¥¼ ìµœëŒ€í•œ í™œìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë“¤ ì‹œì¥ì—ì„œëŠ” í›¨ì”¬ ë” ë‚˜ì€ ìˆ˜ìµì„±ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ í° ì„±ê³µì„ ê±°ë‘ê³  ìˆì£ . ì•ì„œ ë§ì”€ë“œë¦° ì„œìœ ëŸ½ì˜ ì„±ì¥ë¥ ì´ 20%ì— ë‹¬í•©ë‹ˆë‹¤. ì €í¬ëŠ” ë§ì€ ì‹œì¥ì—ì„œ ì ìœ ìœ¨ì„ ë¹¼ì•—ì•„ ì˜¤ê³  ìˆìŠµë‹ˆë‹¤. ì„œìœ ëŸ½ì—ì„œ ë‹¤ìˆ˜ì˜ ê±°ë˜ì²˜ë¥¼ í™•ë³´í–ˆê³ , ëª¨ë“  ì§ì ‘ íŒë§¤ ì‹œì¥ì—ì„œ ì•½ 10% ì •ë„ ì¦ê°€í–ˆìŠµë‹ˆë‹¤. Preserveì™€ ìµœì†Œì¹¨ìŠµ í”Œë«í¼ì´ ì‹¤ì œë¡œ ì´ëŸ¬í•œ ì„±ì¥ì˜ ìƒë‹¹ ë¶€ë¶„ì„ ê²¬ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì œê°€ ë³´ê¸°ì— ì´ê²ƒì´ ì €í¬ì˜ í•µì‹¬ ì„±ì¥ ë™ë ¥ì´ ë  ê²ƒì´ê³ , ìˆ˜ìµì„± í–¥ìƒì—ë„ ë„ì›€ì´ ë  ê²ƒì…ë‹ˆë‹¤. ì§€ê¸ˆê¹Œì§€ ìƒë‹¹í•œ ì§„ì „ì„ ì´ë¤˜ë‹¤ê³  ìƒê°í•˜ë©°, ì´ëŠ” 4ë¶„ê¸°ë¥¼ ê±°ì³ 2026ë…„ ê·¸ë¦¬ê³  ê·¸ ì´í›„ê¹Œì§€ ê³„ì†ë  ê²ƒì…ë‹ˆë‹¤.<br><br>íŒŒì´í”„ë¼ì¸ì— ëŒ€í•œ ëª‡ ê°€ì§€ ì§ˆë¬¸ìœ¼ë¡œ ë§ˆë¬´ë¦¬í•˜ê² ìŠµë‹ˆë‹¤. ê·€ì‚¬ëŠ” í•­ìƒ ìŠ¤ìŠ¤ë¡œë¥¼ ì—¬ì„± ê±´ê°• íšŒì‚¬ë¡œ ì„¤ëª…í•´ ì™”ìŠµë‹ˆë‹¤. ë§ì€ íˆ¬ììë“¤ì´ JEMì— ëŒ€í•´ì„œëŠ” ì˜ ëª¨ë¥´ê³  ìˆëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. JEM í”„ë¡œê·¸ë¨ë¶€í„° ë§ì”€ë“œë¦¬ìë©´, í˜„ì¬ ì§„í–‰ ìƒí™©ê³¼ í–¥í›„ ê¸°íšŒì— ëŒ€í•´ì„œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>ì‚¬ì‹¤ ì´ í”„ë¡œê·¸ë¨ì— ëŒ€í•´ì„œëŠ” ë§ì´ ì–¸ê¸‰í•˜ì§€ ì•ŠëŠ” í¸ì…ë‹ˆë‹¤. ë‹¹ì¥ ëˆˆì•ì˜ ê³¼ì œë“¤ì´ ì›Œë‚™ ë§ê¸° ë•Œë¬¸ì´ì£ . ë¯¸êµ­ ë‚´ ìœ ë°©í™•ëŒ€ìˆ ê³¼ ì¬ê±´ ì ì‘ì¦ì„ ë³´ë©´, JEMì˜ ê²½ìš° íŒŒì´í”„ë¼ì¸ìƒ ì¢€ ë” í›„ìˆœìœ„ ê¸°íšŒë¼ê³  ë³¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì‹œì¥ ê·œëª¨ ì¸¡ë©´ì—ì„œëŠ” ìƒë‹¹íˆ í° ê¸°íšŒê°€ ë  ìˆ˜ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤.<br><br>ìš°ì„ ì€ ì¤‘ë‚¨ë¯¸ ì‹œì¥ì—ì„œ ë¨¼ì € ì¶œì‹œí•  ê³„íšì´ë©°, ì‹œê¸°ëŠ” 2026ë…„ ë§ì—ì„œ 2027ë…„ ì •ë„ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì€ ë¯¸êµ­ê³¼ ìœ ëŸ½ì˜ ê·œì œ ê²½ë¡œì— ë”°ë¼ ë§ì´ ì¢Œìš°ë  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì¤‘ë‚¨ë¯¸ì˜ ê²½ìš° ê·œì œ ì¸¡ë©´ì—ì„œ ì¢€ ë” ìˆ˜ì›”í•  ê²ƒìœ¼ë¡œ íŒë‹¨ë©ë‹ˆë‹¤. ìœ ë°© í™•ëŒ€ ì‹œì¥ì—ì„œ ìš°ë¦¬ê°€ ê°€ì§„ ê¸°íšŒë¥¼ ì¶©ë¶„íˆ í™œìš©í•˜ê³  ë‚˜ë©´, ê·¸ê²ƒì´ 2028ë…„ ì´í›„ ì„±ì¥ì„ ê²¬ì¸í•˜ëŠ” ë™ë ¥ì´ ë  ê²ƒì…ë‹ˆë‹¤.<br><br>Matt Taylor: JEMì´ ë¬´ì—‡ì¸ì§€, ê·¸ ê°€ì¹˜ ì œì•ˆê³¼ í•´ê²°í•˜ê³ ì í•˜ëŠ” ë¯¸ì¶©ì¡± ìˆ˜ìš”ì— ëŒ€í•´ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?<br><br>ë„¤, ë‘”ë¶€ í™•ëŒ€ ì‹œì¥ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ì´ ì‹œì¥ì€ ê·œëª¨ê°€ ìƒë‹¹í•˜ê³  ì§€ë‚œ ëª‡ ë…„ê°„ ì„±ì¥í•´ì™”ìŠµë‹ˆë‹¤. í˜„ì¬ ì´ìš© ê°€ëŠ¥í•œ ê¸°ìˆ ë“¤ì€ ìƒë‹¹íˆ ìˆ˜ì¤€ ì´í•˜ì…ë‹ˆë‹¤. í˜ì‹ ì´ë¼ê³  í•  ë§Œí•œ ê²ƒì´ ê±°ì˜ ì—†ì—ˆìŠµë‹ˆë‹¤. ì†”ì§íˆ ë§ì”€ë“œë¦¬ë©´, ì‚¬ìš©ë˜ëŠ” ì¼ë¶€ ì£¼ì‚¬ì œë‚˜ í•„ëŸ¬ëŠ” ìƒë‹¹íˆ ìœ„í—˜í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ìµœì†Œ ì¹¨ìŠµ í¬íŠ¸í´ë¦¬ì˜¤ì˜ í•µì‹¬ ê¸°ìˆ ë“¤, ì¦‰ ì£¼ì… ì¥ì¹˜ì™€ ì„í”Œë€íŠ¸ë¥¼ ë‘”ë¶€ í™•ëŒ€ìˆ (gluteal augmentation)ì— ì ìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. Peterê°€ ì–¸ê¸‰í–ˆë“¯ì´ ì•„ì§ ì„ìƒ ë‹¨ê³„ì— ìˆê³  ê³„ì† ê°œë°œ ì¤‘ì…ë‹ˆë‹¤. ì§€ê¸ˆê¹Œì§€ ë³¸ ê²°ê³¼ëŠ” ë§¤ìš° ê³ ë¬´ì ì…ë‹ˆë‹¤. ì´ê²ƒì€ íŒŒì´í”„ë¼ì¸ ì œí’ˆìœ¼ë¡œ, Peterê°€ ë§í•œ ëŒ€ë¡œ 2027ë…„ ì´í›„ì— ê¸°ì—¬í•  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ê¸°íšŒëŠ” ì¶©ë¶„í•©ë‹ˆë‹¤.<br><br>ì €í¬ëŠ” ìƒë‹¹íˆ ë…íŠ¹í•˜ê³  ì°¨ë³„í™”ëœ ì œí’ˆì„ ë³´ìœ í•˜ê³  ìˆë‹¤ê³  ë¯¿ìœ¼ë©°, ì•ìœ¼ë¡œ ëª‡ ë…„ê°„ ë” ë§ì€ ì†Œì‹ì„ ì „í•´ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>ì¬ë¯¸ìˆëŠ” ì§ˆë¬¸ìœ¼ë¡œ ë§ˆë¬´ë¦¬í•˜ì‹œë„¤ìš”. ì¸ìŠ¤íƒ€ê·¸ë¨ì—ì„œ ì¸ê¸°ê°€ ë§ìœ¼ì‹œë˜ë°ìš”.<br><br>Rajë¥¼ ë§Œë‚˜ë³´ì‹¤ë˜ìš”?<br><br>ë„¤.<br><br>íšŒì‚¬ ë§ì”€ì´ì‹œì£ . ë¸Œëœë“œ ì•°ë°°ì„œë” ê³„ì•½ë„ ì²´ê²°í•˜ì…¨ê³  ê·¸ ë°©ì‹ìœ¼ë¡œ ë§ˆì¼€íŒ…ë„ ì§„í–‰í•˜ê³  ê³„ì‹ ë°ìš”. ë¸Œëœë“œ ì¸ì§€ë„ë¥¼ ë†’ì´ê¸° ìœ„í•œ ì „ëµê³¼ ì˜¨ë¼ì¸ ë§ˆì¼€íŒ…ì„ í†µí•´ ë§Œë“¤ì–´ì§€ê³  ìˆëŠ” í™”ì œì„±ì— ëŒ€í•´ ì¢€ ë” ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?<br><br>ë„¤, íŠ¹íˆ ë¯¸êµ­ ì‹œì¥ì—ì„œ ì´ëŸ° íš¨ê³¼ë¥¼ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë©”ê±´ íŠ¸ë ˆì´ë„ˆ ìº í˜ì¸ì„ ì§„í–‰í–ˆëŠ”ë°, ì´ê²Œ ì •ë§ í° ì„±ê³µì„ ê±°ë’€ìŠµë‹ˆë‹¤. ë‹¨ìˆœíˆ ê´€ì‹¬ì„ ë„ëŠ” ê²ƒë¿ë§Œ ì•„ë‹ˆë¼, ì‹¤ì œë¡œ í•´ë‹¹ í”„ë¡œê·¸ë¨ì„ í†µí•´ ìœ ì…ëœ í™˜ì ìˆ˜ë„ ì¶”ì í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. <br><br>ë˜í•œ ì „ë°˜ì ìœ¼ë¡œ ì—…ê³„ ë‚´ì—ì„œ ìƒë‹¹í•œ í™”ì œë¥¼ ë§Œë“¤ì–´ë‚¼ ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ ì¤‘ ì¼ë¶€ëŠ” ì €í¬ê°€ ì£¼ë„í•œ ê²ƒì´ê³ , ìƒë‹¹ ë¶€ë¶„ì€ ì§‘ë„ì˜ë“¤ì´ ë§Œë“¤ì–´ë‚¸ ê²ƒì´ê¸°ë„ í•©ë‹ˆë‹¤. ì–´ë–¤ ë©´ì—ì„œëŠ” ë¯¸êµ­ ì‹œì¥ì— ì‹¤ì§ˆì ì¸ í˜ì‹ ì´ ë§ì´ ë‚˜ì˜¤ì§€ ì•Šì•˜ë˜ ê²ƒ ê°™ìŠµë‹ˆë‹¤. ì €í¬ê°€ ì§„ì…í•´ì„œ ë‹¤ì–‘í•œ ì œí’ˆì„ ì œê³µí•˜ë©´ì„œ, ì €í¬ê°€ í•˜ê³  ìˆëŠ” ì¼ë“¤ê³¼ í•¨ê»˜ ì™¸ê³¼ì˜ë“¤ë„ ë§¤ìš° í° ê´€ì‹¬ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì™¸ê³¼ì˜ë“¤ì´ ë§ì€ ê²Œì‹œë¬¼ì„ ì˜¬ë¦¬ê³  ì¬ê³µìœ í•˜ëŠ” ê²ƒì„ ë³¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì‹¤ì œë¡œ ì„±ì¥ì„ ê²¬ì¸í•˜ëŠ” ë° í° ì—­í• ì„ í–ˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì €í¬ì—ê²Œ ë§¤ìš° íŠ¹ë³„í•œ ì ì€ í™˜ìë“¤ì´ ì§ì ‘ ì°¾ì•„ì™€ì„œ ì™¸ê³¼ì˜ì™€ ìƒë‹´í•  ë•Œ ëª¨í‹°ë°”ë¥¼ êµ¬ì²´ì ìœ¼ë¡œ ìš”ì²­í•œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ë…¸ë ¥ì— ëŒ€í•´ ë§¤ìš° ìë¶€ì‹¬ì„ ëŠë¼ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì‹œì¥ ì¹¨íˆ¬ìœ¨ê³¼ í™œìš©ë¥ ì„ ë†’ì´ëŠ” ë° ì‹¤ì§ˆì ìœ¼ë¡œ ë„ì›€ì´ ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì¶”ì„¸ëŠ” 2026ë…„ê³¼ ê·¸ ì´í›„ì—ë„ ê³„ì†ë  ê²ƒì…ë‹ˆë‹¤.<br><br>ì¢‹ìŠµë‹ˆë‹¤. ì œ ê³„ì•½ì„œë¥¼ ê¸°ë‹¤ë¦¬ê³  ìˆê² ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë‹¹ì‹ ì´ ì ì ˆí•œ ëŒ€ìƒì¸ì§€ëŠ” í™•ì‹¤í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤.<br><br>ì•Œê² ìŠµë‹ˆë‹¤. ì‹œê°„ ë‚´ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ë²ˆ ê±´ì— ê´€ì‹¬ ê°€ì ¸ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤.<br><br>ê°ì‚¬í•©ë‹ˆë‹¤.<br><br>ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Establishment Labs 2025 Jefferies ì»¨í¼ëŸ°ìŠ¤ ì£¼ìš” ë‚´ìš©<br><br>## í•µì‹¬ ìš”ì•½<br><br>â€¢ **ë¯¸êµ­ ì‹œì¥ ì§„ì¶œ ì„±ê³µ**: FDA ìŠ¹ì¸ í›„ ì²« í•´ 1,300ê°œ ê±°ë˜ì²˜ í™•ë³´, Q4 ë§ ê¸°ì¤€ ì•½ 20% ì‹œì¥ì ìœ ìœ¨ ë‹¬ì„± ì˜ˆìƒ. ê²½ìŸì‚¬ ëŒ€ë¹„ ìš°ìˆ˜í•œ ì•ˆì „ì„±(ê¸°ê¸° ê´€ë ¨ í•©ë³‘ì¦ 1% ë¯¸ë§Œ)ê³¼ í˜ì‹ ì  ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë°”íƒ•ìœ¼ë¡œ ë¹ ë¥¸ ì‹œì¥ ì¹¨íˆ¬ ì¤‘. 2026ë…„ ìµœëŒ€ 15ëª…ì˜ ì˜ì—…ì¸ë ¥ ì¶”ê°€ íˆ¬ì… ê³„íš.<br><br>â€¢ **ìˆ˜ìµì„± ê°œì„  ë° í˜„ê¸ˆíë¦„ ì „í™˜ ëª©í‘œ**: ë¯¸êµ­ ì‹œì¥ì˜ ë†’ì€ ê°€ê²©(ê¸€ë¡œë²Œ í‰ê·  ëŒ€ë¹„ 2ë°° ì´ìƒ)ìœ¼ë¡œ ë§¤ì¶œì´ì´ìµë¥ ì´ 70% ëŒíŒŒ. EBITDA í‘ì ë‹¬ì„± í›„ 2026ë…„ í˜„ê¸ˆíë¦„ í‘ì ì „í™˜ ëª©í‘œ. ëŒ€ê·œëª¨ ì¸í”„ë¼ íˆ¬ì ì™„ë£Œë¡œ í–¥í›„ ì¦ë¶„ ë§¤ì¶œì˜ ë†’ì€ ì´ìµë¥  ê¸°ëŒ€.<br><br>â€¢ **ì œí’ˆ ë¼ì¸ í™•ëŒ€**: 2026ë…„ Q1 ìµœì†Œì¹¨ìŠµ ì œí’ˆ Preserv ë¯¸êµ­ ì¶œì‹œ ì˜ˆì •($30M+ ë§¤ì¶œ ëª©í‘œ), ì—°ë§ ì¬ê±´(Recon) ì ì‘ì¦ PMA ì œì¶œ ê³„íšìœ¼ë¡œ ì‹œì¥ ê·œëª¨ 2ë°° í™•ëŒ€ ì „ë§. ìµœì†Œì¹¨ìŠµ í¬íŠ¸í´ë¦¬ì˜¤(Mia, Preserv)ê°€ ìœ ëŸ½ ì§ì ‘ ì‹œì¥ì—ì„œ 20%+ ì„±ì¥ ê²¬ì¸ ì¤‘.<br><br>â€¢ **ì¤‘êµ­ ì‹œì¥ ë„ì „ê³¼ì œ**: ê±°ì‹œê²½ì œ ì•…í™”ì™€</p>
    <hr style="margin:50px 0;">
    
</body></html>